Cargando…

Tertiary Lymphatic Structures in Primary Hepatic Carcinoma: Controversy Cannot Overshadow Hope

Tertiary lymphoid structures (TLSs) are organized aggregates of immune cells found in the tumor microenvironment. TLS can influence primary hepatic carcinoma (PHC) occurrence and have an active role in cancer. TLS can promote or inhibit the growth of PHC depending on their location, and although ava...

Descripción completa

Detalles Bibliográficos
Autores principales: Jia, Weili, Zhang, Tianchen, Yao, Qianyun, Li, Jianhui, Nie, Ye, Lei, Xinjun, Mao, Zhenzhen, Wang, Yanfang, Shi, Wen, Song, Wenjie
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9278517/
https://www.ncbi.nlm.nih.gov/pubmed/35844587
http://dx.doi.org/10.3389/fimmu.2022.870458
_version_ 1784746203839201280
author Jia, Weili
Zhang, Tianchen
Yao, Qianyun
Li, Jianhui
Nie, Ye
Lei, Xinjun
Mao, Zhenzhen
Wang, Yanfang
Shi, Wen
Song, Wenjie
author_facet Jia, Weili
Zhang, Tianchen
Yao, Qianyun
Li, Jianhui
Nie, Ye
Lei, Xinjun
Mao, Zhenzhen
Wang, Yanfang
Shi, Wen
Song, Wenjie
author_sort Jia, Weili
collection PubMed
description Tertiary lymphoid structures (TLSs) are organized aggregates of immune cells found in the tumor microenvironment. TLS can influence primary hepatic carcinoma (PHC) occurrence and have an active role in cancer. TLS can promote or inhibit the growth of PHC depending on their location, and although available findings are controversial, they suggest that TLS have a protective role in PHC tissues and a non-protective role in paracancerous tissues. In addition, the cellular composition of TLS can also influence the outcome of PHC. As an immunity marker, TLS can act as a marker of immunotherapy to predict its effect and help to identify patients who will respond well to immunotherapy. Modulation of TLS formation through the use of chemokines/cytokines, immunotherapy, or induction of high endothelial vein to interfere with tumor growth has been studied extensively in PHC and other cancers. In addition, new tools such as genetic interventions, cellular crosstalk, preoperative radiotherapy, and advances in materials science have been shown to influence the prognosis of malignant tumors by modulating TLS production. These can also be used to develop PHC treatment.
format Online
Article
Text
id pubmed-9278517
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-92785172022-07-14 Tertiary Lymphatic Structures in Primary Hepatic Carcinoma: Controversy Cannot Overshadow Hope Jia, Weili Zhang, Tianchen Yao, Qianyun Li, Jianhui Nie, Ye Lei, Xinjun Mao, Zhenzhen Wang, Yanfang Shi, Wen Song, Wenjie Front Immunol Immunology Tertiary lymphoid structures (TLSs) are organized aggregates of immune cells found in the tumor microenvironment. TLS can influence primary hepatic carcinoma (PHC) occurrence and have an active role in cancer. TLS can promote or inhibit the growth of PHC depending on their location, and although available findings are controversial, they suggest that TLS have a protective role in PHC tissues and a non-protective role in paracancerous tissues. In addition, the cellular composition of TLS can also influence the outcome of PHC. As an immunity marker, TLS can act as a marker of immunotherapy to predict its effect and help to identify patients who will respond well to immunotherapy. Modulation of TLS formation through the use of chemokines/cytokines, immunotherapy, or induction of high endothelial vein to interfere with tumor growth has been studied extensively in PHC and other cancers. In addition, new tools such as genetic interventions, cellular crosstalk, preoperative radiotherapy, and advances in materials science have been shown to influence the prognosis of malignant tumors by modulating TLS production. These can also be used to develop PHC treatment. Frontiers Media S.A. 2022-06-29 /pmc/articles/PMC9278517/ /pubmed/35844587 http://dx.doi.org/10.3389/fimmu.2022.870458 Text en Copyright © 2022 Jia, Zhang, Yao, Li, Nie, Lei, Mao, Wang, Shi and Song https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Immunology
Jia, Weili
Zhang, Tianchen
Yao, Qianyun
Li, Jianhui
Nie, Ye
Lei, Xinjun
Mao, Zhenzhen
Wang, Yanfang
Shi, Wen
Song, Wenjie
Tertiary Lymphatic Structures in Primary Hepatic Carcinoma: Controversy Cannot Overshadow Hope
title Tertiary Lymphatic Structures in Primary Hepatic Carcinoma: Controversy Cannot Overshadow Hope
title_full Tertiary Lymphatic Structures in Primary Hepatic Carcinoma: Controversy Cannot Overshadow Hope
title_fullStr Tertiary Lymphatic Structures in Primary Hepatic Carcinoma: Controversy Cannot Overshadow Hope
title_full_unstemmed Tertiary Lymphatic Structures in Primary Hepatic Carcinoma: Controversy Cannot Overshadow Hope
title_short Tertiary Lymphatic Structures in Primary Hepatic Carcinoma: Controversy Cannot Overshadow Hope
title_sort tertiary lymphatic structures in primary hepatic carcinoma: controversy cannot overshadow hope
topic Immunology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9278517/
https://www.ncbi.nlm.nih.gov/pubmed/35844587
http://dx.doi.org/10.3389/fimmu.2022.870458
work_keys_str_mv AT jiaweili tertiarylymphaticstructuresinprimaryhepaticcarcinomacontroversycannotovershadowhope
AT zhangtianchen tertiarylymphaticstructuresinprimaryhepaticcarcinomacontroversycannotovershadowhope
AT yaoqianyun tertiarylymphaticstructuresinprimaryhepaticcarcinomacontroversycannotovershadowhope
AT lijianhui tertiarylymphaticstructuresinprimaryhepaticcarcinomacontroversycannotovershadowhope
AT nieye tertiarylymphaticstructuresinprimaryhepaticcarcinomacontroversycannotovershadowhope
AT leixinjun tertiarylymphaticstructuresinprimaryhepaticcarcinomacontroversycannotovershadowhope
AT maozhenzhen tertiarylymphaticstructuresinprimaryhepaticcarcinomacontroversycannotovershadowhope
AT wangyanfang tertiarylymphaticstructuresinprimaryhepaticcarcinomacontroversycannotovershadowhope
AT shiwen tertiarylymphaticstructuresinprimaryhepaticcarcinomacontroversycannotovershadowhope
AT songwenjie tertiarylymphaticstructuresinprimaryhepaticcarcinomacontroversycannotovershadowhope